Menu Back toImpact of COVID-19 on Clinical Trial Execution

DIA 2021 Global Annual Meeting

Impact of COVID-19 on Clinical Trial Execution

Session Chair(s)

Mary Jo  Lamberti, PhD, MA

Mary Jo Lamberti, PhD, MA

  • Director of Sponsored Research, Research Assistant Professor
  • Tufts Center for the Study of Drug Development, United States
Senior clinical operations executives at major pharmaceutical and biotech companies within the US shared their insights and lessons learned regarding transition to remote and virtual clinical trials due to COVID-19 through in-depth interviews.
Learning Objective : Describe how COVID-19 has impacted the execution of ongoing clinical trials at pharmaceutical and biotech organizations, including remote and virtual approaches adopted; Discuss how the pandemic will influence clinical trial development in the long-term including increased use of telehealth and other technologies.


Melanie  Goodwin, MS, MSc

Supporting Clinical Trial Recruitment During COVID-19

Melanie Goodwin, MS, MSc

  • Director, Patient Recruitment Programs
  • Pfizer Inc, United States
Craig H Lipset, MPH

Decentralized Trials Scale and Commitment Following the Pandemic

Craig H Lipset, MPH

  • Co-Chair
  • Decentralized Trials and Research Alliance (DTRA), United States